Lucia Keilmann

Lucia Keilmann

Auto-generated profile, based on publicly available information

Lucia Keilmann

Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2017 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MWMarkus Wallwiener
Markus Wallwiener
LMLina Matthies
Lina Matthies
ESElisabeth Simoes
Elisabeth Simoes
LKLucia Keilmann
Lucia Keilmann
AHAndreas D Hartkopf
Andreas D Hartkopf
SBSara Yvonne Brucker
Sara Yvonne Brucker
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

7 August 2017 in JMIR Cancer
Verified
Journal Article
Open access
AHAndreas D Hartkopf
Andreas D Hartkopf
DGDr. Joachim Graf
Dr. Joachim Graf
ESElisabeth Simoes
Elisabeth Simoes
LKLucia Keilmann
Lucia Keilmann
NSNina Sickenberger
Nina Sickenberger
MWMarkus Wallwiener
Markus Wallwiener
Patient-Centered Innovations, Education and Technology for Cancer Care and Cancer Research

22 January 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
LMLina Maria Matthies
Lina Maria Matthies
FTFlorin-Andrei Taran
Florin-Andrei Taran
LKLucia Keilmann
Lucia Keilmann
ASAndreas Schneeweiss
Andreas Schneeweiss
ESElisabeth Simoes
Elisabeth Simoes
MWMarkus Wallwiener
Markus Wallwiener
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The most frequent malignant disease in women is breast cancer. In the metastatic setting, quality of life is the primary therapeutic goal and systematic treatment has only limited effect on survival rates; therefore, the concept of Health-related Quality of Life (HRQoL) and measurement of Patient Reported Outcomes (PRO) is gaining more and more importance in the therapy setting of diseases such as breast cancer. One of the frequently used questionnaires for measuring HRQoL in breast cancer patients is the Functional Assessment of Cancer Therapy - Breast (FACT-B). Currently, paper-based surveys still predominate as only a few reliable and validated electronic-based questionnaires are available. EPRO tools of the FACT-B questionnaire with proven reliability are missing so far. Objective: The aim of this study was to analyze the reliability of tablet-based measurement of FACT-B in German language in adjuvant (curative) and metastatic breast cancer patients. Methods: Paper- and tablet-based questionnaires were completed by a total of 106 female adjuvant and metastatic breast cancer patients, recruited as part of the ePROCOM and PEPPER study. All patients were required to complete the electronically based (ePRO) and paper-based version of the FACT-B. A frequency analysis was performed to determine descriptive sociodemographic characteristics. Both dimensions of reliability [parallel forms reliability (Wilcoxon test) and test of internal consistency (Spearman’s rho)] and agreement rates for single items, Kendall’s tau for each subscale and total score were analyzed. Results: High correlations were shown for both dimensions of reliability (parallel forms reliability and internal consistency) in the patient’s response behavior between paper-based and electronically based questionnaires. Regarding the reliability test of parallel forms no significant differences were found in 35 of 37 single items, while significant correlations in the test for consistency were found in all 37 single items, in all 5 sum individual item subscale scores, as well as in total FACT B score. Conclusions: The ePRO version of the FACT-B questionnaire is reliable for breast cancer patients in both the adjuvant and metastatic setting, showing highly significant correlations with the paper-based version in almost all questions all subscales and the total score.

8 February 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
DGDr. Joachim Graf
Dr. Joachim Graf
NSNina Sickenberger
Nina Sickenberger
KBKatharina Brusniak
Katharina Brusniak
LMLina Maria Matthies
Lina Maria Matthies
TDThomas M Deutsch
Thomas M Deutsch
MWMarkus Wallwiener
Markus Wallwiener
Background: One in eight women is diagnosed with breast cancer in the course of their life. As systematic palliative treatment has only a limited effect on survival rates, the concept of health-related quality of life (HRQoL) was developed for measurement of patient-centered outcomes. Various studies have already demonstrated the reliability of paper-based patient-reported outcome (pPRO) and electronic patient-reported outcome (ePRO) surveys and that the 2 means of assessment are equally valid. Objective: The aim of this study was to analyze the acceptance and evaluation of a tablet-based ePRO app for breast cancer patients and to examine its suitability, effort, and difficulty in the context of HRQoL and sociodemographic factors. Methods: Overall, 106 women with adjuvant or advanced breast cancer were included in a 2-center study at 2 major university hospitals in Germany. Patients were asked to answer HRQoL and PRO questionnaires both on a tablet on-site using a specific eHealth assessment website and on paper. The suitability, effort, and difficulty of the app and self-reported technical skills were also assessed. Only the results of the electronically acquired data are presented here. The results of the reliability of the pPRO data have already been published elsewhere. Results: Patients regarded the ePRO assessment as more suitable (80/106, 75.5%), less stressful (73/106, 68.9%), and less difficult (69/106, 65.1%) than pPRO. The majority of patients stated that ePRO assessment improves health care in hospitals (87/106, 82.1%). However, evaluation of ePROs depended on the level of education (P=.003) in the dimensions of effort and difficulty (regression analysis). The app was rated highly in all categories. HRQoL data and therapy setting did not show significant correlations with the app’s evaluation parameters. Conclusions: The results indicate that ePRO surveys are feasible for measuring HRQoL in breast cancer patients and that those patients prefer ePRO assessment to pPRO assessment. It can also be seen that patients consider ePRO assessment to improve hospital health care. However, studies with larger numbers of patients are needed to develop apps that address the needs of patients with lower levels of education and technical skills.

8 December 2022 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
SMSarah Meister
Sarah Meister
EDEva-Maria Dreyer
Eva-Maria Dreyer
LHLaura Hahn
Laura Hahn
MTMarilena Thomann
Marilena Thomann
LKLucia Keilmann
Lucia Keilmann
ABAlexander Burges
Alexander Burges
Purpose: There are different studies worldwide, which have shown a higher risk of mental disorders due to the COVID-19 pandemic. One aim of this study was to identify influencing factors of the psychological burden related to the COVID-19 pandemic and the impact on the development of postpartum depression. Further, the role of individual stress and coping strategies was analyzed in this context. Materials and methods: Between March and October 2020, 131 women in obstetric care at the LMU Clinic Munich completed a questionnaire at consecutive stages during their perinatal period. The times set for the questionnaire were before birth, 1 month, 2 months, and 6 months after birth. The questionnaire was designed to evaluate the psychological burden related to the COVID-19 pandemic. For this a modified version of the Stress and coping inventory (SCI) and the Edinburgh Postnatal Depression Scale (EPDS) was used. Results: We could show that the psychological burden related to the COVID-19 pandemic influenced the EPDS score 1, 2 and 6 months after birth. In addition, the prenatal stress and individual coping strategies affected the EPDS and the burden related to the COVID-19 pandemic before and after birth significantly. Conclusion: An association of the psychological burden related to the COVID-19 pandemic with the risk of developing postpartum depressive symptoms could be shown in this study. In this context, the separation of the partner and the family was recognized as an important factor. Furthermore, the SCI was identified as an effective screening instrument for identifying mothers with an increased risk of postpartum depression. Hereby allowing primary prevention by early intervention or secondary prevention by early diagnosis.

Verified
Journal Article
Open access
PDF file
CBChristina Buschmann
Christina Buschmann
LULaura Unverdorben
Laura Unverdorben
JKJulia Knabl
Julia Knabl
SHStefan Hutter
Stefan Hutter
SMSarah Meister
Sarah Meister
ABAlexander Burges
Alexander Burges
Galectins are known to play an important role in immunoregulatory processes and autoimmune diseases. Galectin-10 is a cytoplasmic protein of human eosinophils and is involved in various eosinophilic diseases. Since increased galectin expression is already detected in the placentas of mothers with gestational diabetes mellitus (GDM), this study focuses on the specific role of galectin-10 and hints at consequences for the diagnosis and therapeutic options of GDM. It is hypothesized that the difference in galectin-10 expression will raise the pathophysiological understanding of gestational diabetes. The study population consists of 80 women: 40 healthy mothers and 40 women suffering from gestational diabetes mellitus. The expression of galectin-10 was analyzed in the syncytiotrophoblast (SCT) and the decidua of the placenta via immunohistochemistry and immunofluorescence double staining. The immunoreactivity score (IRS) was used for evaluation. The results in this study were significant for an overexpression of galectin-10 in GDM placentas compared with the control group. The syncytiotrophoblast showed overexpression in the nucleus and the cytoplasm, whereas expression of galectin-10 in the decidua was significant in the cytoplasm only. This study identified the expression changes in galectin-10 in placental tissue between healthy and GDM mothers and intensified the understanding of gestational diabetes. Assuming that gestational diabetes mellitus is involved in inflammatory processes, galectin-10 might play a role in the development and maintenance of GDM. Further investigation is required to strengthen these findings.